Hongyue Yan
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
Journal: The Journal of dermatological treatment
Published: July 15, 2026
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM313 in Healthy Participants: An Open-Label/Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial.
Journal: Clinical and translational science
Published: May 20, 2025
Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: March 17, 2025
An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial.
Journal: Nature communications
Published: November 14, 2024
Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.
Journal: Nature medicine
Published: August 30, 2024
Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial.
Journal: EClinicalMedicine
Published: March 15, 2023
Anemia is associated with long-term exposure to PM2.5 and its components: a large population-based study in Southwest China.
Journal: Therapeutic advances in hematology
Published: February 21, 2023
Ambient PM2.5 Components Are Associated With Bone Strength: Evidence From a China Multi-Ethnic Study.
Journal: The Journal of clinical endocrinology and metabolism
Published: February 13, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026